Pharming (PHAR) Gains from Sales and Divestitures (2025 - 2026)
Pharming's (PHAR) quarterly Gains from Sales and Divestitures came in at -$3.7 million in Q4 2025, down 17068.18% YoY from N/an in Q4 2024, and down 17068.18% on a QoQ basis from $22000.0 in Q4 2024.
Powered by 
Analysis
Pharming (PHAR) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends
Pharming (PHAR) has 2 years of Gains from Sales and Divestitures data on file, last reported at -$3.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Pharming | 781.07 Mn | 621.57 Mn | 141.47 Mn |